{"data":[{"vaccine_id":5402,"vaccine_name":"AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine","pathogen_id":99,"type":"Other","description":"A cancer vaccine containing the three frame shift peptides (FSP) AIM2(-1), HT001(-1) and TAF1B(-1), with potential immunomodulating activity. Upon administration, the AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine may induce an immune response against microsatellite instability (MSI) colorectal cancer-associated antigens. Frame shift mutations of AIM2 (absent in melanoma 2, an interferon-inducible protein), HT001 (asteroid homolog 1 or ASTE1, with an unknown function) and TAF1B (TATA box-binding protein-associated RNA polymerase I B, a transcription factor) are seen in MSI-positive colorectal cancers and may be associated with malignant transformation, tumor progression and the presence of tumor-infiltrating lymphocytes. These FSPs all have one-base deletions. NCT01461148 [Ref4547:NCIT_C99129].","status":"Clinical trial","vo_id":"VO_0007215","manufacturer":null,"is_combination_vaccine":"No"},{"vaccine_id":12104,"vaccine_name":"Brucella abortus F0F1-type ATP synthase alpha subunit vaccine","pathogen_id":8,"type":"Subunit vaccine","description":"Live attenuated vaccines S19 and RB51 are used to control bovine brucellosis but have safety issues for humans and pregnant cattle; this study aims to identify novel candidate proteins from B. abortus cell envelope for safer vaccine development. Immune response: Several new immunogenic proteins identified by Western blot using antisera from infected bovine and human patients, indicating potential to elicit immune response. [Ref7086:Connolly et al, 2006]","status":"Research","vo_id":"VO_0009186","manufacturer":null,"is_combination_vaccine":"No"},{"vaccine_id":1553,"vaccine_name":"Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.F1)","pathogen_id":146,"type":"Inactivated or \"killed\" vaccine","description":null,"status":"Licensed","vo_id":"VO_0002063","manufacturer":"Intervet Inc.","is_combination_vaccine":"No"},{"vaccine_id":1554,"vaccine_name":"Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.F1)","pathogen_id":142,"type":"Inactivated or \"killed\" vaccine","description":null,"status":"Licensed","vo_id":"VO_0002063","manufacturer":"Intervet Inc.","is_combination_vaccine":"No"},{"vaccine_id":6127,"vaccine_name":"CAdV-1 F1301 Strain Vaccine","pathogen_id":177,"type":"Inactivated or \"killed\" vaccine","description":"CAdV-1 F1301 strain inactivated vaccine can effectively protect against challenge with virulent CAdV-1 in silver foxes. [Ref5911:Fu et al., 2022]","status":"Research","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":3971,"vaccine_name":"Chinese S. japonicum M6-Sj-F1 Vaccine Vector","pathogen_id":242,"type":"Recombinant vector vaccine","description":"Because chemotherapy is currently the main effective method to treat schistosomiasis, but it doesn't prevent reinfection, there has been a need to create a vaccine that can safely express the pathogenic antigen and elicit protection against the disease.  This vectored vaccine has been shown to partially protect laboratory mice from S. japonicum challenge, making it a good candidate for schistosomiasis prevention [Ref2886:Wang et al., 2013].","status":"Research","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":3088,"vaccine_name":"Dust mite pDf11 DNA vaccine","pathogen_id":114,"type":"DNA vaccine","description":null,"status":"Research","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":4067,"vaccine_name":"ESAT-6-gpi DNA vaccine combined with B16F10-ESAT-6-gpi/IL-21 vaccine","pathogen_id":99,"type":"DNA and tumor vaccine","description":"Mice immunized with the glycosylphosphatidylinositol (GPI) anchored 6-kDa early-secreted antigenic target (ESAT-6) DNA vaccine (ESAT-6-gpi) and the tumour vaccine B16F10-ESAT-6-gpi/IL-21 might significantly enhance immune responses and antimelanoma efficacy. Our experimental results indicated that the anti-ESAT-6 antibody induced by the DNA vaccine ESAT-6-gpi bound ESAT-6 to the surface of tumour vaccine to activate a complement classical pathway and resulted in the B16F10 tumour cell lysis and apoptosis, which served as a potential trigger for breaking melanomatous immune tolerance to elicit an initiation of natural antimelanoma immunity [Ref2998:He et al., 2013].","status":"Research","vo_id":"VO_0007603","manufacturer":null,"is_combination_vaccine":"1"},{"vaccine_id":1821,"vaccine_name":"Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.20)","pathogen_id":156,"type":"Live, attenuated vaccine","description":null,"status":"Licensed","vo_id":"VO_0001851","manufacturer":"Pfizer, Inc.","is_combination_vaccine":"No"},{"vaccine_id":1822,"vaccine_name":"Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.20)","pathogen_id":153,"type":"Live, attenuated vaccine","description":null,"status":"Licensed","vo_id":"VO_0001851","manufacturer":"Pfizer, Inc.","is_combination_vaccine":"No"},{"vaccine_id":1823,"vaccine_name":"Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.20)","pathogen_id":120,"type":"Live, attenuated vaccine","description":null,"status":"Licensed","vo_id":"VO_0001851","manufacturer":"Pfizer, Inc.","is_combination_vaccine":"No"},{"vaccine_id":1824,"vaccine_name":"Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.21)","pathogen_id":156,"type":"Live, attenuated vaccine","description":null,"status":"Licensed","vo_id":"VO_0001852","manufacturer":"Merial, Inc.","is_combination_vaccine":"No"},{"vaccine_id":1825,"vaccine_name":"Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.21)","pathogen_id":153,"type":"Live, attenuated vaccine","description":null,"status":"Licensed","vo_id":"VO_0001852","manufacturer":"Merial, Inc.","is_combination_vaccine":"No"},{"vaccine_id":1826,"vaccine_name":"Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.21)","pathogen_id":120,"type":"Live, attenuated vaccine","description":null,"status":"Licensed","vo_id":"VO_0001852","manufacturer":"Merial, Inc.","is_combination_vaccine":"No"},{"vaccine_id":1902,"vaccine_name":"Flavobacterium Columnare Avirulent Live Culture Vaccine (USDA: 17F1.00)","pathogen_id":158,"type":"Live vaccine","description":null,"status":"Licensed","vo_id":"VO_0001740","manufacturer":"Intervet Inc.","is_combination_vaccine":"No"},{"vaccine_id":3571,"vaccine_name":"Lassa fever virus recombinant vector vaccine YF17D/LASV-GP1 expressing GP1","pathogen_id":17,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":3572,"vaccine_name":"Lassa fever virus recombinant vector vaccine YF17D/LASV-GP2 encoding GP2","pathogen_id":17,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":5966,"vaccine_name":"LEISH-F1+MPL-SE","pathogen_id":115,"type":"Subunit vaccine","description":"A Leishmaniasis subunit vaccine made of LEISH-F1+MPL-SE [Ref5579:Nascimento et al., 2010]","status":"Clinical trial","vo_id":"VO_0004266","manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":3099,"vaccine_name":"LEISH-F1+MPL-SE vaccine","pathogen_id":97,"type":"Subunit vaccine","description":null,"status":"Clinical trial","vo_id":"VO_0004266","manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":56,"vaccine_name":"Microencapsulated Caf1 and LcrV vaccine","pathogen_id":11,"type":"Subunit vaccine","description":"Current killed whole cell vaccines have been shown to cause a number of transient side effects, require frequent boosting to maintain immunity, and their efficacy against pneumonic infection is questionable. Thus, a new vaccine for plague based on the protective protein sub-units capsular Fraction 1 (Caf1) and LcrV is under development.  The Caf1 molecule is a temperature-regulated capsular protein of Y. pestis which is maximally expressed at 37 °C and which has a role in resistance of phagocytosis. The LcrV antigen of Y. pestis is a 37 kDa secreted protein that is known to have a role in modulation of host defence mechanisms by down-regulating production of IFN-Î³ and TNF-Î± and and up-regulation of the anti-inflammatory cytokine IL-10. It is also believed to act as a virulence factor with a key role in the Type III secretion system of Y. pestis. Immunisation with recombinant LcrV antigen adsorbed to the adjuvant alhydrogel has been shown to confer protection against virulent challenge by both the sub-cutaneous and airborne routes. The use of the rCaf1 and rLcrV subunits in combination has been shown to have an additive effect on protection in murine models of infection and the two sub-units when formulated with alhydrogel are being taken forward into clinical trials as a vaccine for human use [Ref59: Elvin et al., 2006]","status":null,"vo_id":"VO_0000837","manufacturer":null,"is_combination_vaccine":"No"},{"vaccine_id":8262,"vaccine_name":"Mutant VEGF165b-MUC1 Fusion Protein Vaccine","pathogen_id":99,"type":"Recombinant subunit fusion protein vaccine","description":"A recombinant fusion protein vaccine consisting of plasmin-resistant VEGF165b mutant (mVEGF165b, containing A111P substitution) genetically fused via an AAY linker to a 24-amino acid MUC1 T-cell epitope peptide (STAPPAHGVTSPDTRPAPGSTAPP) derived from the Mucin1 VNTR region. The mVEGF165b component serves dual functions as both a protein carrier to enhance peptide stability and immunogenicity, and as an antigen to elicit anti-VEGF antibodies. Immunization induces high-titer anti-VEGF antibodies (1:1,400,000 titer) that reduce regulatory T cell (Treg) proportions, promote tumor blood vessel maturation, and enhance CD8+ T-cell tumor infiltration. The vaccine stimulates MUC1-specific cytotoxic T-lymphocyte responses, with CD8+ IFN-γ+ T cells increased 10-fold compared to control and 2-fold compared to individual components. In preventive BALB/c mouse models using Mucin1-expressing EMT-6 breast cancer cells, immunization extended median survival to 25 days versus 15 days in controls and demonstrated comparable efficacy to combined administration of separate mVEGF165b and MUC1 components. The MUC1 peptide targets aberrantly glycosylated Mucin1 overexpressed in more than 90% of breast and other cancers [Ref6849:Liang et al., 2024].","status":"Research","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":6346,"vaccine_name":"pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine","pathogen_id":99,"type":"DNA vaccine","description":"A polyepitope plasmid DNA vaccine containing the mammalian expression vector pUMVC3 encoding epitopes derived from three tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2; ERBB2) and insulin-like growth factor 1 receptor (IGF1R), with potential immunostimulating and antineoplastic activities. The vaccine This activates the immune system to mount a combined response from specific T helper type 1 (Th1) cells, memory T-cells and cytotoxic T-lymphocytes (CTL) against IGFBP2-, HER2-, and IGF1R-expressing tumor cells. [Ref6123:NCIT_C127910] This vaccine may prevent cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast cancer in which all signs and symptoms have disappeared. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells. It is given in combination with sargramostim. [Ref6122:NCT02780401]","status":"Clinical trial","vo_id":"VO_0007729","manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":4286,"vaccine_name":"rB-HPIV3-F1","pathogen_id":271,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":5996,"vaccine_name":"rB-HPIV3-F1","pathogen_id":212,"type":"Recombinant vector vaccine","description":null,"status":"Licensed","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":4177,"vaccine_name":"RCN-F1-V (Yersinia pestis F1 and V)","pathogen_id":11,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0004692","manufacturer":null,"is_combination_vaccine":"0"}],"meta":{"page":1,"per_page":25,"count":25,"total":35}}